Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

Clinical implications of antigen transfer mechanisms from malignant to dendritic cells

“…The first observations were made in experimental myelomas, and it has been speculated that these types of mechanisms can be important in understanding the therapeutic effects of anti-idiotypic humoral responses in malignancies of lymphoid origin. Moreover, it has been repeatedly noted, even in clinical trials, that in vitro DC pulsing with either immunoglobulin alone or tumor idiotype conjugated with keyhole limpet hemocyanin (KLH ) can induce cellular immune responses in vivo upon reinfusion of the pulsed DC into the patient [101][102][103][104]. These results suggest that the Fc receptors expressed by DC may internalize tumor-specific idiotype-bearing immunoglobulins alone or as part of immunoconjugates (immunoglobulin chemically complexed to KLH).…”

Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK

“…Recent studies with protein-loaded dendritic cells have demonstrated clinical activity (Timmerman et al, 2002), and dendritic cells have the advantage of efficient antigen uptake and presentation, as well as the expression of the full range of accessory molecules required for an efficient immunodynamic effect.…”

RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma

“…Vaccination strategies using autologous dendritic cells (DC) to prime tumor-specific T cells and overcome aspects of immune incompetence in cancer patients have received the greatest attention. [1][2][3] The hypothesis is that prior to their injection in patients, ex vivo generated DC can be loaded with tumor-associated antigens which are then degraded by the proteasome into short peptides if necessary, transported into the endoplasmic reticulum, packaged in the groove of newly synthesized major histocompatibility complex (MHC) molecules and delivered as peptide-MHC (pMHC) complexes to the cell membrane. Engagement of the appropriate T-cell receptor (TCR) by these pMHC complexes conveys signals that, in the context of additional costimulatory interactions, activate the T cells.…”